EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Longitudinal on-treatment circulating tumor DNA as a biomarker for real-time dynamic risk monitoring in cancer patients: The EP-SEASON study

Jiawei Lv, Ling-Xin Xu, Zhi-Xuan Li, Li Lin, Chen-Fei Wu, Ting-Qiu Quan, Zi-Cheng Zhen, Wen-Fei Li, Ling-Long Tang, Yan-Ping Mao, Lei Chen, Rui Guo und 10 weitere

Cancer Cell · 2024-08 · 42 (8) · 1401-1414.e4

DOI: 10.1016/j.ccell.2024.07.001 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Cancer Cell, 2024-08. Verfasst von Jiawei Lv und 21 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Cli…. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Circulating Tumor DNA, Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms. Die Arbeit wurde bisher 100-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Overseas Expertise Introduction Project for Discipline Innovation, China Postdoctoral Science Foundation, National Postdoctoral Program for Innovative Talents.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recurrence risks of cancer patient can change during treatment as a result of treatment-related tumor evolution. However, biomarkers that can monitor these changes are lacking. Here, we investigated whether tracking circulating tumor DNA (ctDNA) dynamics through liquid biopsy can inform real-time recurrence risk. Nasopharyngeal carcinoma (NPC) provides an ideal model where cell-free Epstein-Barr virus (EBV) DNA (cfEBV DNA), a ctDNA, can be sensitively detected. We conducted the EP-SEASON study (NCT03855020) and prospectively recruited 1,000 NPC patients undergoing per-protocol cfEBV DNA assessments at 11 time points and receiving sequential chemo-radiotherapy. Longitudinal cfEBV DNA displayed distinct patterns during neoadjuvant chemotherapy and radiotherapy. Despite the prognostic significance of cfEBV DNA at each time point, real-time recurrence risks changed in sync with cfEBV DNA dynamics. Furthermore, we identified phenotypes of whole-course ctDNA changing dynamics associated with different survival outcomes. In conclusion, tracking longitudinal on-treatment ctDNA can forecast real-time recurrence risk, facilitating risk-adapted, individualized patient management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biomarkers, TumorCirculating Tumor DNANasopharyngeal CarcinomaNasopharyngeal NeoplasmsNeoplasm Recurrence, LocalAdultAgedFemaleHumansMaleMiddle AgedDNA, ViralEpstein-Barr Virus InfectionsHerpesvirus 4, HumanLiquid BiopsyLongitudinal StudiesPrognosisProspective Studies

Stichwörter der Autor:innen

EP-SEASON studycell-free EBV DNAchanging dynamicslongitudinal circulating tumor DNAnasopharyngeal carcinomareal-time recurrence risks

Substanzen

Biomarkers, TumorCirculating Tumor DNADNA, Viral

Autor:innen und Institutionen

  • State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center…
  • Department of Molecular Diagnostics, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
  • Clinical Trial Centre, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.

Förderung

  • Overseas Expertise Introduction Project for Discipline Innovation
  • China Postdoctoral Science Foundation
  • National Postdoctoral Program for Innovative Talents
  • National Natural Science Foundation of China
  • Higher Education Discipline Innovation Project
  • Natural Science Foundation of Guangdong Province

Zitieren

APA

Lv, J., Xu, L. X., Li, Z. X., Lin, L., Wu, C. F., Quan, T. Q., Zhen, Z. C., Li, W. F., Tang, L. L., Mao, Y. P., Chen, L., Guo, R., Zhang, L. L., Ai, X. L., Wu, S. Y., Hao, M. Y., Wei, D., Li, J. B., Ma, J., …, & Sun, Y. (2024). Longitudinal on-treatment circulating tumor DNA as a biomarker for real-time dynamic risk monitoring in cancer patients: The EP-SEASON study. Cancer Cell, 42(8), 1401-1414.e4. https://doi.org/10.1016/j.ccell.2024.07.001

Vancouver

Lv J, Xu LX, Li ZX, Lin L, Wu CF, Quan TQ, et al. Longitudinal on-treatment circulating tumor DNA as a biomarker for real-time dynamic risk monitoring in cancer patients: The EP-SEASON study. Cancer Cell. 2024;42(8):1401-1414.e4. doi:10.1016/j.ccell.2024.07.001

BibTeX
@article{Lv2024,
  author = {Lv, Jiawei and Xu, Ling-Xin and Li, Zhi-Xuan and Lin, Li and Wu, Chen-Fei and Quan, Ting-Qiu and Zhen, Zi-Cheng and Li, Wen-Fei and Tang, Ling-Long and Mao, Yan-Ping and Chen, Lei and Guo, Rui and Zhang, Lu-Lu and Ai, Xin-Lei and Wu, Shi-Yue and Hao, Meng-Yu and Wei, Denghui and Li, Ji-Bin and Ma, Jun and Chen, Yu-Pei and Zhou, Guan-Qun and Sun, Ying},
  title = {Longitudinal on-treatment circulating tumor DNA as a biomarker for real-time dynamic risk monitoring in cancer patients: The EP-SEASON study},
  journal = {Cancer Cell},
  year = {2024},
  volume = {42},
  number = {8},
  pages = {1401--1414.e4},
  doi = {10.1016/j.ccell.2024.07.001}
}
Kostenlos starten →